Autologous hematopoietic stem cell transplantation in tandem with anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma.

被引：0
|
作者：
Yang, Xiuxiu [1 ]
Zhang, Peiling [1 ]
Cao, Yang [1 ]
Wang, Jue [1 ]
Zhou, Mi [1 ]
Li, Chunrui [1 ]
Zhou, Jianfeng [1 ]
Huang, Liang [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7532
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
    Zhang, Peiling
    Yang, Xiuxiu
    Cao, Yang
    Wang, Jue
    Zhou, Mi
    Chen, Liting
    Wei, Jia
    Mao, Zekai
    Wang, Di
    Xiao, Yi
    Zhu, Haichuan
    Zhang, Shangkun
    Zhang, Tongcun
    Zhang, Yicheng
    Zhou, Jianfeng
    Huang, Liang
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [2] Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
    Peiling Zhang
    Xiuxiu Yang
    Yang Cao
    Jue Wang
    Mi Zhou
    Liting Chen
    Jia Wei
    Zekai Mao
    Di Wang
    Yi Xiao
    Haichuan Zhu
    Shangkun Zhang
    Tongcun Zhang
    Yicheng Zhang
    Jianfeng Zhou
    Liang Huang
    Experimental Hematology & Oncology, 11
  • [3] Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients
    D. Wang
    C. Zeng
    B. Xu
    J.-H. Xu
    J. Wang
    L.-J. Jiang
    Q.-X. Wang
    C.-R. Li
    N. Wang
    L. Huang
    Y.-C. Zhang
    Y. Xiao
    J.-F. Zhou
    Blood Cancer Journal, 10
  • [4] Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients
    Wang, D.
    Zeng, C.
    Xu, B.
    Xu, J. -H.
    Wang, J.
    Jiang, L. -J.
    Wang, Q. -X.
    Li, C. -R.
    Wang, N.
    Huang, L.
    Zhang, Y. -C.
    Xiao, Y.
    Zhou, J. -F.
    BLOOD CANCER JOURNAL, 2020, 10 (01)
  • [5] Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
    Ramos, Carlos A.
    Grover, Natalie S.
    Beaven, Anne W.
    Lulla, Premal D.
    Wu, Meng-Fen
    Ivanova, Anastasia
    Wang, Tao
    Shea, Thomas C.
    Rooney, Cliona M.
    Dittus, Christopher
    Park, Steven I.
    Gee, Adrian P.
    Eldridge, Paul W.
    McKay, Kathryn L.
    Mehta, Birju
    Cheng, Catherine J.
    Buchanan, Faith B.
    Grilley, Bambi J.
    Morrison, Kaitlin
    Brenner, Malcolm K.
    Serody, Jonathan S.
    Dotti, Gianpietro
    Heslop, Helen E.
    Savoldo, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) : 3794 - +
  • [6] Anti-CD30 Chimeric Antigen Receptor T Cell Therapy for CD30+ Relapsed/Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients
    Wang, Di
    Xiao, Yi
    Li, Chunrui
    Wang, Na
    Huang, Liang
    Zhang, Yicheng
    Zhang, Tongcun
    Zhou, Jianfeng
    BLOOD, 2018, 132
  • [7] CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy
    Marques-Piubelli, Mario L.
    Kim, Do Hwan
    Medeiros, L. Jeffrey
    Lu, Wei
    Khan, Khaja
    Gomez-Bolanos, Lorena Isabel
    Rodriguez, Saxon
    Parra, Edwin R.
    Ok, Chi Young
    Aradhya, Akanksha
    Solis, Luisa M.
    Nieto, Yago L.
    Steiner, Raphael
    Ahmed, Sairah
    Vega, Francisco
    HISTOPATHOLOGY, 2023, 83 (01) : 143 - 148
  • [8] Expression of Concern: CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy
    不详
    HISTOPATHOLOGY, 2024, 84 (03) : 574 - 574
  • [9] T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30+ cutaneous lymphoma cells
    Hombach, A
    Muche, JM
    Gerken, M
    Gellrich, S
    Heuser, C
    Pohl, C
    Sterry, W
    Abken, H
    GENE THERAPY, 2001, 8 (11) : 891 - 895
  • [10] T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30+ cutaneous lymphoma cells
    A Hombach
    J M Muche
    M Gerken
    S Gellrich
    C Heuser
    C Pohl
    W Sterry
    H Abken
    Gene Therapy, 2001, 8 : 891 - 895
12345